UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
__________________
FORM
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
June
26, 2006 (June 22, 2006)
Date
of
Report (Date of earliest event reported)
___________________
COMPETITIVE
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
1-8696
|
36-2664428
|
|
(State
or other jurisdiction of
incorporation)
|
(Commission
File
Number )
|
(I.R.S.
Employer
Identification
No.)
|
1960
Bronson Road, Fairfield, Connecticut 06824
(Address
of principal executive
offices) (Zip
Code)
(203)
255-6044
(Registrant’s
telephone number, including area code)
________________________
Not
Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
□
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
□
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
□
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
□
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item
8.01 Other
Events.
On
June
22, 2006, Competitive Technologies, Inc. (“CTT”) announced that that
the
United States Supreme Court ruled
in
favor of Metabolite Laboratories, Inc. (“MLI”) and CTT dismissing the writ of
certiorari previously granted to Laboratory Corporation of America Holdings
d/b/a LabCorp (“LabCorp”) in a homocysteine patent case. LabCorp had filed for
the writ of certiorari seeking to overturn an infringement ruling in a patent
case in which CTT's patent rights, and those of its clients, had been upheld
by
both the U.S. District Court and the Court of Appeals of the Federal Circuit.
The matter originated in 1999, when MLI and CTT filed a complaint against
LabCorp alleging breach of contract, patent infringement and unpaid royalties
for performing homocysteine assays using patents owned by CTT.
A
copy of
the press release is attached as Exhibit 99.1.
Item
9.01. Financial
Statements and Exhibits
(c) Exhibits.
| Exhibit
99.1 |
Press
release dated June 22,
2006.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
COMPETITIVE
TECHNOLOGIES, INC. |
|
|
|
| Date: June
26, 2006 |
By: |
/s/ Michael
D. Davidson |
| |
Name: Michael
D. Davidson |
| |
Title: Vice
President and Chief Financial
Officer |
EXHIBIT
INDEX
| Exhibit
99.1 |
Press
release dated June 22, 2006 announcing that United
States Supreme Court ruled
in favor of Metabolite Laboratories, Inc. and CTT dismissing the
writ of
certiorari previously granted to Laboratory Corporation of America
Holdings d/b/a LabCorp in a homocysteine patent
case.
|